Evidence map›Paper›PMID 28814725›Full record

ArticleNature communications2017

Micromotor-enabled active drug delivery for in vivo treatment of stomach infection.

Berta Esteban-Fernández de Ávila, Pavimol Angsantikul, Jinxing Li, Miguel Angel Lopez-Ramirez, Doris E Ramírez-Herrera, Soracha Thamphiwatana, Chuanrui Chen, Jorge Delezuk, Richard Samakapiruk, Valentin Ramez and 3 more

Erratum issuedOpen access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 158 papers.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed
44.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 603 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Micro/Nano-Motors for Enhanced Tumor Diagnosis and Therapy.International journal of molecular sciences · 2025
    Review
  17. Article
  18. A roadmap for next-generation nanomotors.Nature nanotechnology · 2025
    Review
  19. Review
  20. Review

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Berta Esteban-Fernández de ÁvilaDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Pavimol AngsantikulDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-1671-9373
Jinxing LiDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Miguel Angel Lopez-RamirezDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Doris E Ramírez-HerreraDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Soracha ThamphiwatanaDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Chuanrui ChenDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Jorge DelezukDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Richard SamakapirukDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Valentin RamezDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Marygorret ObonyoDepartment of Medicine, University of California San Diego, La Jolla, CA, 92093, USA.
Liangfang ZhangDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA. zhang@ucsd.edu.ORCID http://orcid.org/0000-0003-0637-0654
Joseph WangDepartment of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA. josephwang@ucsd.edu.
University of California San Diego · US

Funding

Innate Antimicrobial Nanotherapeutics for the Treatment of H. pylori InfectionR01DK095168 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, LIANGFANG · 2012 to 2016
$1.6M
NIDDK NIH HHS R01 DK095168
6 · The paper itself

Abstract

Advances in bioinspired design principles and nanomaterials have led to tremendous progress in autonomously moving synthetic nano/micromotors with diverse functionalities in different environments. However, a significant gap remains in moving nano/micromotors from test tubes to living organisms for treating diseases with high efficacy. Here we present the first, to our knowledge, in vivo therapeutic micromotors application for active drug delivery to treat gastric bacterial infection in a mouse model using clarithromycin as a model antibiotic and Helicobacter pylori infection as a model disease. The propulsion of drug-loaded magnesium micromotors in gastric media enables effective antibiotic delivery, leading to significant bacteria burden reduction in the mouse stomach compared with passive drug carriers, with no apparent toxicity. Moreover, while the drug-loaded micromotors reach similar therapeutic efficacy as the positive control of free drug plus proton pump inhibitor, the micromotors can function without proton pump inhibitors because of their built-in proton depletion function associated with their locomotion.Nano- and micromotors have been demonstrated in vitro for a range of applications. Here the authors demonstrate the in-vivo therapeutic use of micromotors to treat H. pylori infection.

Indexed as

AnimalsAnti-Bacterial AgentsClarithromycinDrug Delivery SystemsDrug Therapy, CombinationGastric DilatationHelicobacter InfectionsHelicobacter pyloriMagnesiumMiceNanotechnologyProton Pump InhibitorsAnti-Bacterial AgentsClarithromycinMagnesiumProton Pump Inhibitors

Identifiers

PMID28814725
PMCPMC5559609
OpenAlexW2742552651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.